GLP-1 RAs in Non-diabetic Obesity - SELECT - Dr. Michael Lincoff (Cleveland, OH, USA)

Dr. Michael Lincoff presents the background, methods and results of the seminal SELECT study, which tested the GLP-1 receptor agonist semaglutide for cardiovascular risk reduction in non-diabetic patients with overweight or obesity. Dr. Lincoff is Principle Investigator of SELECT, which he presented as Late Breakting Trial at the Annual Meeting of the American Heart Association (AHA) in November 2023, simultaneously with its publication in the New England Journal of Medicine.
Dr. Lincoff is an interventional cardiologist and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He is Vice Chairman for Research of the Department of Cardiovascular Medicine at the Cleveland Clinic. His research activities focus on development of metabolic or antithrombotic therapies to prevent or reduce progression of atherosclerosis.
The interview was recorded on January 17th, 2024.
Moderators: Prof. Dr. Florian Custodis (Saarbrücken, Germany), Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern, Germany), and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).
Articles discussed:
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators.
N Engl J Med 2023
doi: 10.1056/NEJMoa2307563
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM.
Am Heart J 2020
doi: 10.1016/j.ahj.2020.07.008
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D'Alessio D; SURPASS-CVOT investigators.
Am Heart J 2024
doi: 10.1016/j.ahj.2023.09.007
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators.
N Engl J Med. 2023
doi: 10.1056/NEJMoa2301972
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M.
Lancet 2023
doi: 10.1016/S0140-6736(23)01163-7
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators.
N Engl J Med. 2023
doi: 10.1056/NEJMoa2306963
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC.
JACC Heart Fail 2023
doi: 10.1016/j.jchf.2023.05.010
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators.
JAMA 2023
doi: 10.1001/jama.2023.24945
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mahaffey KW, Mann JFE, Mersebach H, Perkovic V, Tuttle K, Pratley R. Nephrol Dial Transplant 2023
doi: 10.1093/ndt/gfad009.
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.
Leggio L, Hendershot CS, Farokhnia M, Fink-Jensen A, Klausen MK, Schacht JP, Simmons WK.
Nat Med 2023
doi: 10.1038/s41591-023-02634-8